Country: United States
Language: English
Source: NLM (National Library of Medicine)
Albumin Human (UNII: ZIF514RVZR) (Albumin Human - UNII:ZIF514RVZR)
CSL Behring LLC
Albumin Human
Albumin Human 25 g in 100 mL
INTRAVENOUS
Albumin is indicated in the emergency treatment of shock and in other similar conditions where the restoration of blood volume is urgent. If there has been considerable loss of red blood cells, transfusion with packed red blood cells is indicated. Albumin or Albumin in either normal saline or dextrose is indicated to prevent marked hemoconcentration and to maintain appropriate electrolyte balance. Albumin is indicated in those clinical situations usually associated with a low concentration of plasma protein and a resulting decreased circulating blood volume. Although diuresis may occur soon after albumin administration has been instituted, best results are obtained if albumin is continued until the normal serum protein level is regained. ALBUMINAR® -25 may be contraindicated in patients with severe anemia or cardiac failure and in patients with a history of allergic reactions to human albumin.
ALBUMINAR® -25 is supplied as a 25% solution. Each product presentation includes a package insert and the components listed in Table 2 below. Store between 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F) [See USP Controlled Room Temperature].
Biologic Licensing Application
ALBUMINAR-25- ALBUMIN (HUMAN) SOLUTION CSL BEHRING LLC ---------- ALBUMIN (HUMAN) USP, 25% ALBUMINAR -25 R ONLY DESCRIPTION Albumin (Human) 25%, ALBUMINAR -25 is a sterile aqueous solution of albumin obtained from large pools of adult human venous plasma by low temperature controlled fractionation according to the Cohn process. It is stabilized with 0.02 M sodium acetyltryptophanate and 0.02 M sodium caprylate and pasteurized at 60°C for 10 hours. All Source Plasma used in the manufacture of this product was tested by FDA-licensed Nucleic Acid Testing (NAT) for HBV, HCV, and HIV-1 and found to be nonreactive (negative). ALBUMINAR -25 is a solution containing in each 100 mL, 25 grams of serum albumin, osmotically equivalent to 500 mL of normal human plasma. The pH of the solution is adjusted with sodium bicarbonate, sodium hydroxide, or acetic acid. Approximate concentrations of significant electrolytes per liter are: sodium - 130-160 mEq; and potassium - n.m.t. 1 mEq. The solution contains no preservative. This product has been prepared in accordance with the requirements established by the Food and Drug Administration and is in compliance with the standards of the United States Pharmacopeia. ALBUMINAR -25 is to be administered by the intravenous route. The heat treatment step employed in the manufacture of ALBUMINAR -25 pasteurization of the final container at 60°C for 10 hours, has been validated in a series of _in vitro_ experiments for its capacity to inactivate Human Immunodeficiency Virus type 1 (HIV-1), and the following model viruses: Bovine Viral Diarrhea Virus (BVDV - an enveloped virus used as a model for hepatitis C virus), Pseudorabies (PrV - a large, enveloped virus), and Encephalomyocarditis Virus (EMC - a small non-enveloped virus). For each virus studied, three independent experiments were conducted using Albumin (Human) 5%, ALBUMINAR -5 and ALBUMINAR -25 with the results provided in Table 1. TABLE 1. VIRAL REDUCTION STUDIES FOR ALBUMINAR -5 AND ALBUMINAR -25 Pasteurization (60°C for 10 hours) Read the complete document